Intellia Therapeutics (NASDAQ:NTLA) Rating Increased to Sell at StockNews.com

StockNews.com upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) to a sell rating in a report published on Friday.

A number of other analysts have also recently weighed in on the stock. Robert W. Baird decreased their price target on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Stifel Nicolaus lowered their target price on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research note on Wednesday, September 11th. JPMorgan Chase & Co. decreased their price target on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 12th. Barclays dropped their price objective on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Chardan Capital decreased their target price on shares of Intellia Therapeutics from $94.00 to $88.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $57.94.

Intellia Therapeutics Stock Up 4.6 %

Shares of NASDAQ NTLA traded up $0.73 during midday trading on Friday, hitting $16.73. The stock had a trading volume of 2,418,301 shares, compared to its average volume of 2,854,846. Intellia Therapeutics has a 1-year low of $13.95 and a 1-year high of $34.87. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of -3.05 and a beta of 1.81. The company has a fifty day moving average price of $19.17 and a 200 day moving average price of $22.22.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. During the same period last year, the firm earned ($1.38) earnings per share. The company’s quarterly revenue was down 24.1% on a year-over-year basis. On average, research analysts forecast that Intellia Therapeutics will post -5.21 EPS for the current year.

Insider Transactions at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the sale, the chief accounting officer now directly owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 3.20% of the company’s stock.

Institutional Trading of Intellia Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC increased its position in Intellia Therapeutics by 9.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 8,894 shares of the company’s stock worth $245,000 after buying an additional 750 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Intellia Therapeutics in the 1st quarter worth about $160,000. Swiss National Bank lifted its position in Intellia Therapeutics by 1.3% in the 1st quarter. Swiss National Bank now owns 167,900 shares of the company’s stock valued at $4,619,000 after purchasing an additional 2,200 shares during the last quarter. Headlands Technologies LLC acquired a new position in Intellia Therapeutics during the 1st quarter valued at about $224,000. Finally, ProShare Advisors LLC grew its position in Intellia Therapeutics by 11.9% in the 1st quarter. ProShare Advisors LLC now owns 23,235 shares of the company’s stock worth $639,000 after purchasing an additional 2,466 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.